anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Pantoprazole
Trial phase: Not Applicable
ATC code: A02BC02 | A02BD04 | A02BD11
SMILES: COc1ccnc(CS(=O)c2nc3ccc(OC(F)F)cc3[nH]2)c1OC
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 25
Group description: Homozygous for CYP2C19 null alleles (*2/*2, *2/*3 or *3/*3, Poor metabolizers) was measured by (13C)Pantoprazole breath test.

[13C]Pantoprazole: [13C]Pantoprazole was administered to EM, IM and PM of CYP2C19 and enzyme activity was measured through breath test and compared among the genotypes
Eligibility criteria:
Inclusion Criteria:

Asian male or female subjects between 18 and 49 years of age, who are in good physical health with no significant medical problems or laboratory test abnormalities. Subjects should have normal liver and kidney function.
Subjects with BMI <30 which will be determined by Metropolitan height and weight tables. Subjects must weigh at least 110 pounds.
Subjects must agree to refrain from taking any prescription and over-the-counter medications, as well as any herbal medications one week before the start of the study and during the study period.
Subjects must agree to refrain from consuming alcohol 48 hours before the start of the study and during the study period.
Subjects must be capable of satisfying protocol requirements and be able to sign written informed consent.

Exclusion Criteria:

Subjects who have a history of intolerance or allergy to the study drug: pantoprazole.
Subjects who have donated blood within the last 60 days of the screening visit or plan to donate blood during the course of the study or within 60 days after study completion.
Subjects who have had treatment with any investigational drug within the past 30 days.
Subjects who have used illegal drugs within three months prior to enrollment.
Female subjects currently taking oral contraceptive birth control pills and who are unwilling or unable to stop oral contraceptives and use a barrier contraceptive method (such as condom, contraceptive foams, etc.) starting from the time of screening phase to the completion of the study.
Female subjects who are pregnant or lactating.
Subjects who are unreliable in the opinion of the study physician.
Intervention: Atenolol
Trial phase: Phase 4
ATC code: C07AB03 | C07BB03 | C07CB03 | C07CB53 | C07DB01 | C07FB03
SMILES: CC(C)NCC(O)COc1ccc(CC(N)=O)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 41
Group description: Atenolol 25 mg once daily - Forced titration occurred in atenolol to 50 mg at week one, and to 100 mg at week two.
Eligibility criteria:
Inclusion Criteria:

At least 18 years of age
Hypertension (untreated or treated with no more then one anti-hypertensive drug)

Exclusion Criteria:

Secondary forms of hypertension (including sleep apnea)
Patients currently treated with two or more antihypertensive drugs
Patients taking antihypertensive drugs with properly measured clinic systolic blood pressure greater then 170mmHg
Isolated systolic hypertension
Other diseases requiring treatment with blood pressure lowering medications
Heart rate less then 55 beats/min (in the absence of beta-blocker therapy)
Known cardiovascular disease including history of angina pectoris, heart failure, presence of a cardiac pacemaker, history of myocardial infarction or revascularization procedure, or cerebrovascular disease (including stroke and TIA)
Known diabetes mellitus (Type 1 or 2)
Renal insufficiency defined as a serum creatinine greater then 1.5mg/dL in males and 1.4mg/dL in females
Primary renal disease
Pregnancy or lactation
History of Raynaud's syndrome
Alcoholism and recreational drug use (due to compliance concerns)
Intervention: Betamethasone
Trial phase: Not Applicable
ATC code: A01AC02 | A07EA04 | C05AA05 | C05AA09 | D07AB19 | D07AC01 | D07BC01 | D07CB04 | D07CC01 | D07XB05 | D07XC01 | D10AA03 | H02AB01 | H02AB02 | R01AD03 | R01AD06 | R01AD53 | R03BA04 | S01BA01 | S01BA06 | S01BB04 | S01CA01 | S01CA05 | S01CB01 | S01CB04 | S02BA06 | S02BA07 | S02CA06 | S03BA01 | S03BA03 | S03CA01 | S03CA06
SMILES: CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)CO
Sex: Female
Age groups: Child | Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 85
Group description: Betamethasone (Celestone) 12 mg IM q 24 hours x 2 doses
Eligibility criteria:
Inclusion Criteria:

Greater than 14 days after first course of antenatal steroids;
Less than 34 weeks of gestation;
Identified by primary physician as continued risk for preterm delivery;
Informed consent

Exclusion Criteria:

Major congenital anomalies
Multiple gestation of triplets or greater
Mother with insulin dependent diabetes
Intervention: LEVONORGESTREL
Trial phase: Not Applicable
ATC code: G03AA07 | G03AB03 | G03AC03 | G03AD01 | G03FA11 | G03FB09
SMILES: [H][C@@]12CCC3=CC(=O)CC[C@]3([H])[C@@]1([H])CC[C@@]1(CC)[C@@]2([H])CC[C@@]1(O)C#C
Sex: Female
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 57
Group description: Oral levonorgestrel
Eligibility criteria:
Inclusion Criteria:

Women 18-45 years old, in need of EC (had unprotected intercourse within 120 hours), willing to give consent for participation in research, willing to comply with the study requirements, and accessible by telephone.
Patients selecting the IUD need to identify themselves as desiring long-term contraception.

Exclusion Criteria:

Current pregnancy,
Had pelvic inflammatory disease or a septic abortion within the past 3 months or gonorrheal or chlamydial infection in the last 60 days,
Current behavior suggesting a high risk for pelvic inflammatory disease
Allergy to copper, or Wilson's disease (for patients selecting Paragard) or allergy to levonorgestrel (for patients selecting Plan B)
Intracavitary of symptomatic uterine fibroids, and abnormalities of the uterus that distort the uterine cavity,
Mucopurulent cervicitis,
A previously placed IUD that has not been removed
Genital bleeding of unknown etiology
Ovarian, cervical or endometrial cancer,
Small uterine cavity
Intervention: Lubiprostone
Trial phase: Not Applicable
ATC code: A06AX03
SMILES: [H][C@@]12CC(=O)[C@H](CCCCCCC(=O)O)[C@@]1([H])CC[C@](O)(C(F)(F)CCCC)O2
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 1
Group description: patient received treatment( lubiprostone)24 mcg po BID for 4 weeks
Eligibility criteria:
Inclusion Criteria:

Age 50-85 years
Diagnosis of Parkinson's disease
Constipation as defined by the Rome III committee
BSFS of more or equal to 1 and less or equal to 3
Normal colonoscopy in the last 5 years( normal defined as absence of obstructive lesions in the colon)
All women subjects will be post menopausal or surgically sterile.

Exclusion Criteria:

Known hypersensitivity reaction to Amitiza ( Lubiprostone)
Known significant adverse effects to previous treatment with Lubiprostone which include; new or worsening abdominal pain, severe diarrhea, nausea, vomiting, and severe headache.
Renal dysfunction with creatinine clearance less than 15 ml/min
Abnormal liver enzymes or history of chronic liver disorder
History of bowel obstruction, , or abdominal adhesions .
Abnormal Colonoscopy ( obstructive lesions within the colon)
Inability to give informed consent
Intervention: Pomalidomide
Trial phase: Phase 1 | Phase 2
ATC code: L04AX06
SMILES: Nc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 65
Group description: All patients enrolled to this Phase II arm started treatment at 0.5mg/day with CC-4047 every day of each 28 day cycle.
Eligibility criteria:
DISEASE CHARACTERISTICS:

Diagnosis of primary and post essential thrombocythemia (ET) or post polycythemia vera (PV) myelofibrosis requiring therapy

De novo presentation (i.e., agnogenic myeloid metaplasia AND post ET or post PV myelofibrosis)
Developed after an antecedent history of PV (i.e., post polycythemic myeloid metaplasia) or essential polycythemia (i.e., post thrombocythemic myeloid metaplasia)
Total hemoglobin < 10 g/dL OR transfusion dependent anemia (defined by a history of ≥ 2 units of red blood cell (RBC) transfusions within the past 28 days for hemoglobin < 8.5 g/dL that was not associated with overt bleeding) OR marked splenomegaly (e.g., ≥ 10 cm below costal margin)

PATIENT CHARACTERISTICS:

Eastern Cooperative Oncology Group (ECOG) performance status 0-2
Absolute neutrophil count (ANC) ≥ 500/μL
Platelet count ≥ 20,000/μL
Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ≤ 3 times upper limit of normal (ULN) (≤ 5 times ULN if attributed to hepatic extramedullary hematopoiesis)
Total bilirubin ≤ 3 times ULN OR direct bilirubin ≤ 2 times ULN
Serum creatinine ≤ 2.0 mg/dL
Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective double-method contraception for ≥ 28 days before, during, and for ≥ 28 days after completion of study treatment
Agrees to abstain from donating blood, semen, or sperm during and for ≥ 28 days after completion of study treatment
Willing to undergo transfusion of blood products (if applicable)
Able to complete questionnaire(s) alone or with assistance
No known HIV positivity, hepatitis B carrier, or active hepatitis C infection
No serious medical condition, psychiatric illness, or any other condition, including the presence of laboratory abnormalities, that (as judged by the treating physician) would preclude giving informed consent or participating in the study or confound the ability to interpret data from the study
No other active malignancies, except basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast
No active deep vein thrombosis or pulmonary embolism that has not been therapeutically anticoagulated

PRIOR CONCURRENT THERAPY:

Recovered from all prior therapy
No prior CC-4047
More than 28 days since prior growth factors, cytotoxic chemotherapeutic agents (e.g., hydroxyurea or anagrelide), corticosteroids, or experimental drugs or therapies
No other concurrent experimental drugs or therapies or cytotoxic chemotherapeutic agents (e.g., hydroxyurea or anagrelide) for myelofibrosis
No concurrent growth factors (including erythropoietin) for myelofibrosis, except G-CSF or pegfilgrastim
No concurrent chronic use (i.e., > 2 weeks) of more than physiologic doses of corticosteroids (dose equivalent to > 10 mg/day of prednisone)
Intervention: VALPROIC ACID
Trial phase: Phase 2
ATC code: N03AG01
SMILES: CCCC(CCC)C(=O)O
Sex: Male
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 15
Group description: Patients receive oral valproic acid twice daily for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients complete quality of life questionnaires at baseline, 6 months, and 1 year.

valproic acid: given orally
Eligibility criteria:
DISEASE CHARACTERISTICS:

Histologically confirmed prostate cancer

Asymptomatic, non-metastatic disease

Biochemical progression after definitive local therapy (radical prostatectomy)

Most recent prostate-specific antigen (PSA) level ≥ 1.0 ng/mL AND rising over the prior value
No clinical or radiological evidence of local progression

PSA doubling time (DT) < 10 months after local therapy (in patients who have not received prior hormone therapy)

At least three PSA values (each at least 4 weeks apart) are required to calculate the PSA-DT
No clinical or radiological evidence of metastatic disease, including bone metastasis

PATIENT CHARACTERISTICS:

ECOG performance status 0-2
Life expectancy > 3 months
Total bilirubin normal
AST/ALT < 2.5 times upper limit of normal
Creatinine ≤ 2.5 mg/dL
Platelet count > 125,000/mm^3
PT and aPTT ≤ 1.3 times above the standard reference
Albumin ≥ 3.5 g/dL
Geographically accessible and willing to participate in all stages of study treatment
No active second malignancy
No known HIV positivity
No active, uncontrolled infection (e.g., hepatitis A, B, or C infection)
No history of allergic reactions attributed to compounds of similar chemical or biological composition to valproic acid
No debilitating medical or psychiatric illness that would preclude giving informed consent or receiving optimal study treatment and follow-up
No history of hepatic disease or significant hepatic dysfunction
No history of pancreatitis
No history of seizure disorder or clinically treated bipolar disorder

PRIOR CONCURRENT THERAPY:

More than 6 months since prior hormone therapy
No prior valproic acid
At least 2 weeks since prior drugs specifically known to interact with valproic acid including, but are not limited to, aspirin, felbamate, rifampin, amitriptyline/nortriptyline, carbamazepine, clonazepam, diazepam, ethosuximide, lamotrigine, phenobarbital, primidone, phenytoin, tolbutamide, warfarin, or zidovudine
No concurrent systemic chemotherapy for prostate cancer
No other concurrent investigational drugs
Intervention: Fasudil
Trial phase: Phase 2
ATC code: C04AX32
SMILES: O=S(=O)(c1cccc2cnccc12)N1CCCNCC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 2
Group description: Fasudil 40 mg three times a day X 14 days

Fasudil Hydrochloride: Fasudil 40 mg three times a day x 14 days
Eligibility criteria:
Inclusion Criteria:

Subjects with >= 70% carotid stenosis (unilateral or bilateral) who are scheduled to undergo elective carotid endarterectomy
Age >= 18 years
Agreement of the operating surgeon for patient to participate

Exclusion Criteria:

Surgery scheduled < 14 days after randomization
Pregnancy
ALT, GGT > 3x upper limit of normal (ULN)
Creatinine > 3.5 mg/dL
Prior intolerance to statins
Reluctance to add or change dosage of statin therapy during study
Intervention: Nadolol
Trial phase: Phase 1 | Phase 2
ATC code: C07AA12 | C07BA12
SMILES: CC(C)(C)NCC(O)COc1cccc2c1CC(O)C(O)C2
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 10
Group description: nadolol: Nadolol, oral taken daily, doses will be escalated every two weeks over 13 weeks following a 2 week run-in.
Eligibility criteria:
Inclusion Criteria:

Pre-bronchodilator FEV1 80% or greater than the predicted value.
PC20 FEV1 ≤4 mg/ml on methacholine challenge test.
Blood Pressure ≥ 100/65mm Hg.
Pulse rate ≥ 60 beats/min.
No significant health issues.
Non-smoker or X-smoker < 10 pack/year.

Exclusion Criteria:

History of upper/lower respiratory tract infection or asthma exacerbation within 6 weeks of first baseline visit.
Currently diagnosed with chronic obstructive pulmonary disease (COPD).
Used any oral or inhaled corticosteroids within 4 weeks of the first baseline visit.
Intervention: MK-2206
Trial phase: Phase 1
SMILES: NC1(c2ccc(-c3nc4ccn5c(=O)[nH]nc5c4cc3-c3ccccc3)cc2)CCC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 3
Group description: Participants receive 30 mg oral MK-2206 every other day (QOD) in repeating 4-week treatment cycles.
Eligibility criteria:
Inclusion Criteria:

Participant must have confirmed locally advanced or metastatic solid tumors that have failed to respond to standard therapy, have gotten worse or have come back after existing therapy
Has normal organ function; is no greater than 2 on the ECOG Performance Scale
Has a negative blood or urine pregnancy test within 72 hours of receiving the first dose of study drug if participant is female
Is able to swallow capsules and has no surgical or bodily condition that will prevent the patient from swallowing and absorbing oral medications on an ongoing basis

Exclusion Criteria:

Participant has had chemotherapy, radiotherapy, biological therapy or surgery within 4 weeks of starting the study and has not recovered from adverse events caused by the treatment
Is currently participating or has participated in a study with an investigational compound or device within 30 days
Has a primary central nervous system tumor
Has a history or current evidence of heart disease, slow heart rate or untreated high blood pressure
Is a known diabetic who is taking insulin or oral antidiabetic therapy
Is pregnant or breastfeeding or planning to become pregnant during the study
Is HIV-positive
Has known history of Hepatitis B or C or active Hepatitis A
Is receiving treatment with oral corticosteroids
Intervention: MK-2206
Trial phase: Phase 1
SMILES: NC1(c2ccc(-c3nc4ccn5c(=O)[nH]nc5c4cc3-c3ccccc3)cc2)CCC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 3
Group description: Participants receive 90 mg oral MK-2206 every week (QW) in repeating 4-week treatment cycles.
Eligibility criteria:
Inclusion Criteria:

Participant must have confirmed locally advanced or metastatic solid tumors that have failed to respond to standard therapy, have gotten worse or have come back after existing therapy
Has normal organ function; is no greater than 2 on the ECOG Performance Scale
Has a negative blood or urine pregnancy test within 72 hours of receiving the first dose of study drug if participant is female
Is able to swallow capsules and has no surgical or bodily condition that will prevent the patient from swallowing and absorbing oral medications on an ongoing basis

Exclusion Criteria:

Participant has had chemotherapy, radiotherapy, biological therapy or surgery within 4 weeks of starting the study and has not recovered from adverse events caused by the treatment
Is currently participating or has participated in a study with an investigational compound or device within 30 days
Has a primary central nervous system tumor
Has a history or current evidence of heart disease, slow heart rate or untreated high blood pressure
Is a known diabetic who is taking insulin or oral antidiabetic therapy
Is pregnant or breastfeeding or planning to become pregnant during the study
Is HIV-positive
Has known history of Hepatitis B or C or active Hepatitis A
Is receiving treatment with oral corticosteroids
Intervention: MK-2206
Trial phase: Phase 1
SMILES: NC1(c2ccc(-c3nc4ccn5c(=O)[nH]nc5c4cc3-c3ccccc3)cc2)CCC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 3
Group description: Participants receive 300 mg oral MK-2206 QW in repeating 4-week treatment cycles.
Eligibility criteria:
Inclusion Criteria:

Participant must have confirmed locally advanced or metastatic solid tumors that have failed to respond to standard therapy, have gotten worse or have come back after existing therapy
Has normal organ function; is no greater than 2 on the ECOG Performance Scale
Has a negative blood or urine pregnancy test within 72 hours of receiving the first dose of study drug if participant is female
Is able to swallow capsules and has no surgical or bodily condition that will prevent the patient from swallowing and absorbing oral medications on an ongoing basis

Exclusion Criteria:

Participant has had chemotherapy, radiotherapy, biological therapy or surgery within 4 weeks of starting the study and has not recovered from adverse events caused by the treatment
Is currently participating or has participated in a study with an investigational compound or device within 30 days
Has a primary central nervous system tumor
Has a history or current evidence of heart disease, slow heart rate or untreated high blood pressure
Is a known diabetic who is taking insulin or oral antidiabetic therapy
Is pregnant or breastfeeding or planning to become pregnant during the study
Is HIV-positive
Has known history of Hepatitis B or C or active Hepatitis A
Is receiving treatment with oral corticosteroids
Intervention: Betamethasone
Trial phase: Phase 1 | Phase 2
ATC code: A01AC02 | A07EA04 | C05AA05 | C05AA09 | D07AB19 | D07AC01 | D07BC01 | D07CB04 | D07CC01 | D07XB05 | D07XC01 | D10AA03 | H02AB01 | H02AB02 | R01AD03 | R01AD06 | R01AD53 | R03BA04 | S01BA01 | S01BA06 | S01BB04 | S01CA01 | S01CA05 | S01CB01 | S01CB04 | S02BA06 | S02BA07 | S02CA06 | S03BA01 | S03BA03 | S03CA01 | S03CA06
SMILES: CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)CO
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 1
Group description: STEROID: Betamethasone; 12 mg intramuscularly x 2 doses 24 hours apart

Betamethasone: 12 mg intramuscularly x 2 doses 24 hours apart
Eligibility criteria:
Inclusion Criteria:

GA < 26 weeks
Maternal age > 18 years of age
Singleton pregnancy
Normal chromosomes
CCAM volume to head circumference ratio (CVR) > 1.4
No maternal medical/surgical contraindications
No evidence of hydrops
Not previously randomization

Exclusion Criteria:

Maternal diabetes or use of insulin
Preterm labor
Multiple congenital anomalies with CCAM
Chromosomal anomaly with CCAM
Multiple gestation pregnancy with CCAM
Not willing to be randomized
Unable or unwilling to return to UCSF for second dose of drug or placebo
CVR < 1.4
Intervention: Chlorine Dioxide
Trial phase: Phase 3
SMILES: [O][Cl+][O-]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 278
Group description: tablet experimental formulation
Eligibility criteria:
Inclusion Criteria:

Onset of pain is within 3 days of first visit
Subject rating of pain must be 40 mm or greater on visual analog scale( VAS)
Ability to discontinue all analgesics, non steroidal anti inflammatory drug (NSAIDs), and other muscle relaxants
Willingness to provide written informed consent
Must be in generally good health

Exclusion Criteria:

Presence of sciatic pain
History of clinically significant spine pathology such as herniated nucleas pulposis, spondylolisthesis, spinal stenosis
Presence of underlying chronic back pain
Neurological signs and symptoms such as numbness, tingling, foot drop, parethesia, unexplained constipation, urinary retention or urinary incontinence
Myocardial infaction within one year of study
Cancer not in remission or in remission less than one year
HIV or other immunodeficiency syndromes
History of osteoporosis or at high risk for vetebral fracture
Underlying rheumatologic disease such as rheumatoid arthritis, ankylosing spondylitis, etc.
Presence of active influenze or other viral syndromes
Morbid obesity basal metabolic index(BMI >39)
Evidence of infection, such as low grade fever or neutrophilia
Existence of any medical/surgical condition that could interfere with the evaluation of the study medication
Known history of alcohol or drug abuse
Injury involving high potential for litigation, including worker's compensation or automobile accidents
Pregnancy or breast feeding
Women of child-bearing potential not abstinent or not practicing a medically acceptable method of contraception
Vertebral body or spinous process, percussive tenderness on physical exam
Any abnormalities in the following tests of both lower extremities: ankle dorsiflexion strength, great toe dorsiflexion strength, absent or hypereflexic Achilles or patellar tendor reflexes, abnormal sensory exam in the medial, dorsal or lateral aspect of the foot and positive straight leg raise test
Urgent medical conditions on comprehensive exam that might indicate a more serious condition should be treated urgently